Evaluation of soluble ST2 as a novel cardiovascular biomarker in patients with acute myocardial infarction

Kavya Suryadevara, Melvin George, Amrita Jena, V. E. Dhandapani, N. Damodharan, Jayasutha J.


Background: Soluble ST-2 has considerable prognostic value and is used as an aid for risk stratification in identifying patients who are at high risk of cardiovascular disease. The main objective of the study was to analyze the level of soluble ST-2 biomarker in patients with acute myocardial infarction and chronic stable angina patients and secondly to evaluate the cardiovascular outcomes after 30 days.

Methods: A total of 71 patients were enrolled into the study, patients were divided into two groups of which 50 patients were in test group (AMI patients) and the remaining 21 patients were in the control group (chronic stable angina). Then, 5ml of blood was collected from the patients and plasma soluble ST-2 was estimated from the sample using ELISA technique. Patients were then followed up to 30 days to ascertain the development of major adverse cardiovascular outcomes.

Results: The median concentration of soluble ST-2 in test group was found to be 213.46pg/ml and in control group was found to be 124.53 pg/ml. Soluble ST-2 correlated significantly with left ventricular ejection fraction (LVEF) between the two groups (P value=0.01). Measurement of soluble ST-2 early after MI assists in the prediction of adverse cardiovascular events. In this study, soluble ST-2 was found to be higher in patients with acute myocardial infarction and also in patients with poor ejection fraction.

Conclusions: Soluble ST-2 is a novel cardiovascular biomarker that is elevated in patients with acute myocardial infarction.


Acute myocardial infarction, Cardiac biomarkers, Cardiovascular events, LVEF, Morbidity, Soluble ST-2

Full Text:



Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction—Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation. 2004;110(5):588-636.

Dhillon OS, Narayan HK, Khan SQ, Kelly D, Quinn PA, Squire IB, et al. Pre-discharge risk stratification in unselected STEMI: is there a role for ST-2 or its natural ligand IL-33 when compared with contemporary risk markers. Int J Cardiol. 2013;167(5):2182-88.

Zhang K, Zhang XC, Mi YH, Liu J. Predicting value of serum soluble ST-2 and interleukin-33 for risk stratification and prognosis in patients with acute myocardial infarction. Chin Med J (Engl). 2013;126(19):3628-31.

Shimpo M, Morrow DA, Weinberg EO, Sabatine MS, Murphy SA, Antman E.M, et al. Serum levels of the interleukin-1 receptor family member ST-2 predict mortality and clinical outcome in acute myocardial infarction. Circulation. 2004;109:2186-90 .

Landesberg G, Shatz V, Akopnik I, Wolf YG, Mayer M, Berlatzky Y, et al. Association of Cardiac Troponin, CK-MB,and Postoperative Myocardial Ischemia With Long-Term Survival After Major Vascular Surgery. Journal of the American College of Cardiology. 2003;42(9):1547-54.

Kehl DW, Iqbal N, Fard A, Kipper BA, Parra Landa ADL, Maisel AS. Biomarkers in acute myocardial injury. Translational Research. 2012;159(4):252-64.

Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, Solomon SD, et al. Expression and Regulation of ST-2, an Interleukin-1 Receptor Family Member, in Cardiomyocytes and Myocardial Infarction. Circulation. 2002;106(23):2961-66.

Trajkovic V, Sweet MJ, Xu D. T1/ST-2–an IL-1 receptor-like modulator of immune responses. Cytokine Growth Factor Rev. 2004;15(2-3):87-95.

Lassus J, Gayat E, Mueller C, Peacock W.F, Spinar J, Harjola V, et al. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: The Multinational Observational Cohort on Acute Heart Failure (MOCA) study. Int J Cardio. 2013;168(3):2186-94.

Manzano-Fernández S, Mueller T, Pascual-Figal A, Truong QA, Januzzi JL Usefulness of Soluble Concentrations of Interleukin Family Member ST-2 as Predictor of Mortality in Patients With Acutely Decompensated Heart Failure Relative to Left Ventricular Ejection Fraction. Am J Cardiol. 2011;107(2):259-67.

Gruson D, Lepoutre T, Ahn SA, Rousseau MF. Increased soluble ST-2 is a stronger predictor of long-term cardiovascular death than natriuretic peptides in heart failure patients with reduced ejection fraction. Int J Cardiol. 2014;172(1):250-2.

Bayes-Genis A, de Antonio M, Vila J, Peñafiel J, Galán A, Barallat J, et al. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST-2 versus galectin-3. J Am Coll Cardiol. 2014;63(2):158-66.

Mueller T, Dieplinger B, Gegenhuber A, Poelz W, Pacher R, Haltmayer M. Increased Plasma Concentrations of Soluble ST-2 are Predictive for 1-Year Mortality in Patients with Acute Destabilized Heart Failure. Clinical Chemistry. 2008;54(4):752-6.

Broch K, Ueland T, Nymo SH, Kjekshus J, Hulthe J, Muntendam P, et al. Soluble ST-2 is associated with adverse outcome in patients with heart failure of ischemic etiology. Eur J Heart Fail. 2012;14(3):268-77.

Dale M, Nicklin MJ. Interleukin-1 receptor cluster: gene organization of IL1R2, IL1R1, IL1RL2 (IL-1 Rrp2), IL1RL1 (T1/ST-2), and IL18R1 (IL-1Rrp) on human chromosome 2q. Genomics. 1999;57(1):177-9.

Pascual-Figal DA, Januzzi JL. The Biology of ST-2: The International ST-2 Consensus Panel. AmJ Cardiol. 2015;115(7):3B-7B.

Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST-2 and induces T helper type 2-associated cytokines. Immunity. 2005;23:479-90.

Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT. Identification of serum soluble ST-2 receptor as a novel heart failure biomarker. Circulation. 2003;107(5):721-26.

Weir RA, Miller AM, Murphy GE, Clements S, Steedman T, Connell JM, et al. Serum soluble ST-2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol. 2010;55(3):243-50.

Demyanets S, Speidl WS, Tentzeris I, Jarai R, Katsaros KM, Farhan S, et al. Soluble ST-2 and interleukin-33 levels in coronary artery disease: relation to disease activity and adverse outcome. PLoS One. 2014;9(4):2080-9.